Cowen Reiterates Outperform Rating on Teladoc (TDOC) Following Raised Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts TDOC Hot Sheet
Rating Summary:
10 Buy, 25 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Cowen analyst Charles Rhyee reiterated an Outperform rating and $161.00 price target on Teladoc (NYSE: TDOC) after the company raised its 2021 revenue guidance to $2.03B at an industry conference (vs. prior $2.015B-$2.025B, consensus of $2.02B), and reiterated its prelim 2022 guide of $2.6B.
Rhyee notes TDOC "also highlighted its value proposition as a mult-channel, fully integrated strategic partner; momentum in multi-product sales; a strong 2022 selling season; and its intentions to expand into value-based care."
For an analyst ratings summary and ratings history on Teladoc click here. For more ratings news on Teladoc click here.
Shares of Teladoc closed at $82.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teladoc (TDOC) PT Raised to $9 at Barclays
- AMD (AMD) PT Raised to $600 at DA Davidson
- Astera Labs (ALAB) PT Lowered to $300 at TD Cowen
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
